Search Orphan Drug Designations and Approvals
-
Generic Name: | 2-(trans-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin6-yl)amino)cyclohexyl)propan-2-ol hydrochloride |
---|---|
Date Designated: | 05/10/2022 |
Orphan Designation: | Treatment of Myelofibrosis |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Sumitomo Pharma America, Inc. 84 Waterford Drive Marlborough, Massachusetts 01752 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-